For the enterprising pharma giant, it can be hard to branch out into new ailments and treatments. Internal R&D teams aren’t assembled overnight. And snapping up rivals’ drugs only works if one knows enough to pick the right horses, and has the scale to squeeze more sales out of them. GSK’s $10.6bn acquisition of cancer biotech Nuvalent shows the UK drugmaker has finally reached that point in the huge growth area that is oncology.
对于有进取心的制药巨头来说，要向新的疾病领域和治疗方法扩张并不容易。内部研发团队不可能一夜之间组建起来。而收购竞争对手的药物，前提是既要有足够的专业判断能力能“押对宝”，又要具备放大销量的规模优势。葛兰素史克(GSK)以106亿美元收购癌症生物科技公司Nuvalent，表明这家英国制药商终于在肿瘤这一巨大增长领域已经具备了这样的条件。
您已阅读16%（601字），剩余84%（3274字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。